We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
In a recent study published in the Journal of Hepatology, researchers reported that the coronavirus disease 2019 (COVID-19) vaccination could elicit a distinct T cell-dominant immune-mediated hepatitis.
Vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to combat the COVID-19 pandemic. Recently, several reports have surfaced indicating autoimmune hepatitis (AIH)-like conditions post-COVID-19 vaccination, not observed during clinical trials. Liver injury has been observed with both vector- and messenger ribonucleic acid (mRNA)-based vaccines with a varying period of vaccination-to-symptom onset.
Study: SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Image Credit: NIAID
In the present study, researchers described the case of a male who presented with acute mixed hepatitis post-first BNT162b2 vaccine dose and severe hepatitis post-second dose.
The patient, aged 52 years, had no medical history except hypothyroidism and developed nausea, pruritus, loss of appetite, and fatigue. The onset of symptoms was about 10 days after the first BNT162b2 dose. Subsequently, the patient developed jaundice, and a liver function test (LFT) indicated acute mixed hepatocellular/cholestatic hepatitis and was admitted to a primary care center after 25 days of first vaccination.
Hepatitis A, B, C, or E virus, cytomegalovirus (CMV), and Epstein-Barr virus- infections were ruled out as the cause based on serological or polymerase chain reaction (PCR) tests. Forty-one days post-first dose, the patient took a second BNT162b2 vaccine, and 20 days after the second dose, the patient had fatigue and nausea. Laboratory testing confirmed the relapse of acute mixed hepatitis, and 26 days after the second vaccination, the case was referred to the tertiary care center.
Autoimmune serological tests revealed mild hyperglobulinemia, antinuclear antibodies (ANA), and borderline positivity for anti-mitochondrial M2 antibody (AMA-M2) and anti-smooth muscle antibodies, while anti-liver kidney microsomal (LKM) antibody tests were negative. The liver biopsy revealed interface hepatitis with moderate lymphoplasmacytic infiltrate and lobular necrotic and apoptotic foci. These clinical findings were consistent with a probable AIH, and the treatment was 9 mg of budesonide/day. In the ensuing weeks, levels of liver enzymes dropped, and another relapse occurred after 39 days of therapy initiation, controlled by systemic steroids and ursodeoxycholic acid. LFTs normalized in eight weeks, and anti-spike (S) antibodies showed no significant fluctuations.
Further, the team found infiltrates of T and B lymphocytes, macrophages, granulocytes, and plasma cells in the liver. A 5.3-fold increase in immune cells was observed relative to control (non-diseased) tissue. The cluster of differentiation 8 (CD8) T lymphocytes was the most abundant among immune cells, a condition unanticipated for AIH. Contrastingly, B and plasma cells were relatively lower, unlike typical AIH presentations, albeit more enriched than controls. Spatial analysis of liver parenchyma for different subsets of immune cells revealed more extensive immune infiltration in the periportal areas. While B and plasma cells were enriched predominantly in the periportal regions, a panlobular distribution was noted for CD8 T lymphocytes. Notably, cytotoxic CD8 T cells (characterized by granzyme B) were highly accumulated, while the levels of other granzyme B-expressing cells remained unchanged.
Next, flow cytometry analyzed intrahepatic and peripheral populations of CD8 T cells in depth. The intrahepatic CD8 T cell pool showed enrichment of markers for activation (CD38) and tissue residency (CD103, CD69, and C-X-C Motif Chemokine Receptor 6 [CXCR6]). CD8 T cells in peripheral blood also expressed CD38. Intriguingly, CD38 expression was markedly higher in the patient (75.9%) than in control (15.4%) matched for post-vaccination time without hepatitis development. A 3.4-fold enrichment of SARS-CoV-2 S-specific CD8 T lymphocytes was noted in the intrahepatic CD8 T cell population compared to peripheral blood.
Moreover, S-specific CD8 T lymphocytes were 10.2-fold more abundant in the peripheral blood than T lymphocytes specific for an Epstein-Barr virus-specific T cell control epitope. A stable frequency of S-specific CD8 T cells was noted in circulation, and the CD38 levels decreased with budesonide therapy. Nevertheless, CD38 expression on CD8 T cells specific for SARS-CoV-2 S protein and other cytotoxic markers were elevated when a relapse occurred during budesonide treatment but normalized after treatment with systemic immunosuppressants.
The researchers noted a slight increase in peripheral immunoglobulins and intrahepatic enrichment of plasma and B cells. Strikingly, cytotoxic CD8 T cells (CD38-expressing) were the most enriched to the extent that they were the most abundant immune cells in the liver.
These observations implicated T cells as the pathogenic cell type associated with the vaccination-related immune hepatitis as the novel AIH subtype. These findings indicated that vaccination with BNT162b2 might cause immune-mediated hepatitis by vaccine-elicited cellular immunity mechanisms.
Posted in: Medical Research News | Disease/Infection News | Pharmaceutical News
Tags: Antibodies, Antibody, Autoimmune Hepatitis, Biopsy, Blood, Cell, Chemokine, Coronavirus, Coronavirus Disease COVID-19, Cytomegalovirus, Cytometry, Epstein-Barr Virus, Fatigue, Flow Cytometry, Frequency, Hepatitis, Hepatitis A, Hepatology, Hypothyroidism, immunity, Jaundice, Kidney, Laboratory, Liver, Muscle, Nausea, Pandemic, Polymerase, Polymerase Chain Reaction, Primary Care, Protein, Pruritus, Receptor, Respiratory, Ribonucleic Acid, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, T-Cell, Vaccine, Virus
Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.
Please use one of the following formats to cite this article in your essay, paper or report:
Sai Lomte, Tarun. (2022, April 25). COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis. News-Medical. Retrieved on May 21, 2022 from https://www.news-medical.net/news/20220425/COVID-19-vaccine-can-elicit-a-distinct-T-cell-dominant-immune-mediated-hepatitis.aspx.
Sai Lomte, Tarun. "COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis". News-Medical. 21 May 2022. <https://www.news-medical.net/news/20220425/COVID-19-vaccine-can-elicit-a-distinct-T-cell-dominant-immune-mediated-hepatitis.aspx>.
Sai Lomte, Tarun. "COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis". News-Medical. https://www.news-medical.net/news/20220425/COVID-19-vaccine-can-elicit-a-distinct-T-cell-dominant-immune-mediated-hepatitis.aspx. (accessed May 21, 2022).
Sai Lomte, Tarun. 2022. COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis. News-Medical, viewed 21 May 2022, https://www.news-medical.net/news/20220425/COVID-19-vaccine-can-elicit-a-distinct-T-cell-dominant-immune-mediated-hepatitis.aspx.
Hepatitis outbreak in kids - are the parents or teachers vexed?
Hepatitis A, B, C, D, or E not identified in any of the new mysterious children’s cases, this news article I’m posting here says. Article above says, “Hepatitis A, B, C, or E virus, cytomegalovirus (CMV), and Epstein-Barr virus- infections were ruled out as the cause based on serological or polymerase chain reaction (PCR) tests.“ Anyway, just surmising, as I’m not an expert. finance.yahoo.com/.../...estigating-165435392.html
"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis" - In 1 person so far out of 4.6 billion people world wide and 200 thousand people in the U.S. who are fully vaccinated.
Other countries have already blown the whistle about covid 19 vaccines causing hepatitis in people. Goes to show you that some countries are actually doing real research while other countries try to hide the truth from people.
Which countries have blown the whistle.
If such blood test was done in 10000 with 500 persons per 5year age groups, results will be alarming. No symptoms is no excuse to eliminate what is going on inside with vax.
In this interview, we speak to Martin Mangold, an applications specialist at BMG LABTECH, about their microplate readers and the essential role they play within life sciences research.
In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables.
In this interview, we speak to Dr. Damini Dey from Cedars-Sinai Medical Center about their latest research that involved using AI to predict heart attacks.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022